Quick Answer
Indaptus Therapeutics, Inc. reported R&D Expense of $9.34 million for fiscal year 2025.
Indaptus Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $9.34M | +28.8% |
| 2024 | $7.25M | -4.9% |
| 2023 | $7.62M | +20.5% |
| 2022 | $6.32M | +150.7% |
| 2021 | $2.52M | -5.0% |
| 2020 | $2.66M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $1.52M | +3.5% | -30.0% |
| June 30, 2025 | $2.17M | +26.4% | -22.9% |
| March 31, 2025 | $2.81M | +76.7% | +91.7% |
| September 30, 2024 | $1.47M | -34.2% | -14.5% |
| June 30, 2024 | $1.71M | +15.8% | +7.7% |
| March 31, 2024 | $1.59M | -15.4% | -28.5% |
| September 30, 2023 | $2.23M | +38.3% | +50.4% |
| June 30, 2023 | $1.48M | -1.7% | -21.2% |
- Indaptus Therapeutics, Inc. showed an increase of +28.8% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Indaptus Therapeutics, Inc.’s r&d expense has grown by 251.8% (from $2.66 million to $9.34 million).
- The most recent figure is from Indaptus Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 17, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: